In vivo function of airway epithelial TLR2 in host defense against bacterial infection.
Decreased Toll-like receptor 2 (TLR2) expression has been reported in patients with chronic obstructive pulmonary disease and in a murine asthma model, which may predispose the hosts to bacterial infections, leading to disease exacerbations. Since airway epithelial cells serve as the first line of respiratory mucosal defense, the present study aimed to reveal the role of airway epithelial TLR2 signaling to lung bacterial [i.e., Mycoplasma pneumoniae (Mp)] clearance. In vivo TLR2 gene transfer via intranasal inoculation of adenoviral vector was performed to reconstitute TLR2 expression in airway epithelium of TLR2(-/-) BALB/c mice, with or without ensuing Mp infection. TLR2 and lactotransferrin (LTF) expression in airway epithelial cells and lung Mp load were assessed. Adenovirus-mediated TLR2 gene transfer to airway epithelial cells of TLR2(-/-) mice reconstituted 30-40% TLR2 expression compared with TLR2(+/+) cells. Such airway epithelial TLR2 reconstitution in TLR2(-/-) mice significantly reduced lung Mp load (an appropriate 45% reduction), coupled with elevated LTF expression. LTF expression in mice was shown to be mainly dependent on TLR2 signaling in response to Mp infection. Exogenous human LTF protein dose-dependently decreased lung bacterial load in Mp-infected TLR2(-/-) mice. In addition, human LTF protein directly dose-dependently decreased Mp levels in vitro. These data indicate that reconstitution of airway epithelial TLR2 signaling in TLR2(-/-) mice significantly restores lung defense against bacteria (e.g., Mp) via increased lung antimicrobial protein LTF production. Our findings may offer a deliverable approach to attenuate bacterial infections in airways of asthma or chronic obstructive pulmonary disease patients with impaired TLR2 function.
Department of Medicine, National Jewish Health and University of Colorado Denver, Denver, Colorado 80206, USA.
Qun
Q
Wu
Di
D
Jiang
Maisha N
MN
Minor
Richard J
RJ
Martin
Hong Wei
HW
Chu
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001424:Bacterial Infections / Q000276:immunology* / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology*; D058491:Bacterial Load / Q000187:drug effects; D004847:Epithelial Cells / Q000187:drug effects / Q000382:microbiology* / Q000473:pathology*; D005786:Gene Expression Regulation / Q000187:drug effects; D018014:Gene Transfer Techniques; D006801:Humans; D007781:Lactoferrin / Q000378:metabolism / Q000494:pharmacology; D008168:Lung / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009177:Mycoplasma pneumoniae / Q000187:drug effects / Q000254:growth & development; D011019:Pneumonia, Mycoplasma / Q000276:immunology* / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology; D051195:Toll-Like Receptor 2 / Q000172:deficiency / Q000235:genetics / Q000276:immunology*
C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D007781:Lactoferrin
Genet Vaccines Ther. 2008 Feb 08;6:5
18261231
Vaccine. 2005 Jan 11;23(8):1029-36
15620476
Arch Immunol Ther Exp (Warsz). 2005 Sep-Oct;53(5):418-27
16314825
Eur Respir J. 2007 Aug;30(2):240-4
17459899
J Immunol. 2008 Sep 15;181(6):4141-9
18768871
Immunobiology. 2004;209(8):599-608
15638128
J Lab Clin Med. 1990 Feb;115(2):148-58
2299262
J Immunol. 2003 Dec 15;171(12):6820-6
14662888
Clin Exp Immunol. 1998 Aug;113(2):157-65
9717963
J Med Microbiol. 2009 Mar;58(Pt 3):322-326
19208881
Biochem Cell Biol. 2002;80(1):7-16
11908645
Am J Respir Crit Care Med. 1998 Sep;158(3):998-1001
9731038
Cell Mol Life Sci. 2005 Nov;62(22):2540-8
16261256
J Biol Chem. 1999 Apr 9;274(15):10219-26
10187807
Infect Immun. 2009 Feb;77(2):714-24
19015258
Clin Chest Med. 2000 Jun;21(2):301-13
10907590
Am J Respir Crit Care Med. 2008 Apr 1;177(7):720-9
18202345
Am J Respir Crit Care Med. 1995 Jun;151(6):2088-92; discussion 2092-3
7767562
FEMS Microbiol Lett. 1997 May 1;150(1):89-94
9163911
Clin Exp Allergy. 2009 Nov;39(11):1754-63
19552640
J Leukoc Biol. 2003 Oct;74(4):479-85
12960260
Hum Gene Ther. 1998 Dec 10;9(18):2661-72
9874264
J Virol. 2004 Dec;78(24):13755-68
15564484
Vet Immunol Immunopathol. 2007 Apr 15;116(3-4):153-62
17306889
Antimicrob Agents Chemother. 2004 Apr;48(4):1242-8
15047526
Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1064-72
17194718
J Med Microbiol. 2007 Mar;56(Pt 3):305-312
17314358
J Infect Dis. 2003 Jan 1;187(1):87-95
12508150
Infect Immun. 2006 Jun;74(6):3325-33
16714560
Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L312-22
16936244
J Immunol. 2007 Sep 15;179(6):3995-4002
17785838
Am J Respir Cell Mol Biol. 2009 Feb;40(2):189-99
18703793
Respir Res. 2005 Jul 08;6:68
16004610
J Immunol. 2001 Jul 1;167(1):375-83
11418673
Biochimie. 2009 Jan;91(1):19-29
18573312
Infect Immun. 2000 Oct;68(10):5816-23
10992490
Am J Respir Cell Mol Biol. 1993 Nov;9(5):547-56
7692897
J Infect Dis. 2006 Jun 15;193(12):1693-702
16703513
J Virol. 1998 Jul;72(7):6014-23
9621064
J Mol Evol. 2003;57 Suppl 1:S21-8
15008400